Company intelligence / Profile preview
Synthekine
- Ownership
- Private
- Development stage
- Other
01
Overview
Currently conducting Phase 1 study of STK-009 + SYNCAR-001 for CD19+ hematologic malignancies (NCT05665062). STK-009 dose escalation is ongoing with a fixed dose of SYNCAR-001 cells that is significantly lower than traditional CD19 CAR-T therapies. Preclinical studies showed significantly more complete responses compared to conventional CD19 CAR-T cell therapy in xenograft efficacy models.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Engineered cytokine therapeuticsCAR-T cell therapies
- Industry
- Biotech
02
Drug pipeline
15 assets14 more assets in the full pipeline.
03
Partnerships
Mentioned having partnerships but specific companies not named
Beyond the preview
Go deeper on Synthekine.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Synthekine.